Cargando…
Therapeutic Advances in Immunotherapies for Hematological Malignancies
Following the success of immunotherapies such as chimeric antigen receptor transgenic T-cell (CAR-T) therapy, bispecific T-cell engager therapy, and immune checkpoint inhibitors in the treatment of hematologic malignancies, further studies are underway to improve the efficacy of these immunotherapie...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569660/ https://www.ncbi.nlm.nih.gov/pubmed/36232824 http://dx.doi.org/10.3390/ijms231911526 |
_version_ | 1784809909398798336 |
---|---|
author | Nogami, Ayako Sasaki, Koji |
author_facet | Nogami, Ayako Sasaki, Koji |
author_sort | Nogami, Ayako |
collection | PubMed |
description | Following the success of immunotherapies such as chimeric antigen receptor transgenic T-cell (CAR-T) therapy, bispecific T-cell engager therapy, and immune checkpoint inhibitors in the treatment of hematologic malignancies, further studies are underway to improve the efficacy of these immunotherapies and to reduce the complications associated with their use in combination with other immune checkpoint inhibitors and conventional chemotherapy. Studies of novel therapeutic strategies such as bispecific (tandem or dual) CAR-T, bispecific killer cell engager, trispecific killer cell engager, and dual affinity retargeting therapies are also underway. Because of these studies and the discovery of novel immunotherapeutic target molecules, the use of immunotherapy for diseases initially thought to be less promising to treat with this treatment method, such as acute myeloid leukemia and T-cell hematologic tumors, has become a reality. Thus, in this coming era of new transplantation- and chemotherapy-free treatment strategies, it is imperative for both scientists and clinicians to understand the molecular immunity of hematologic malignancies. In this review, we focus on the remarkable development of immunotherapies that could change the prognosis of hematologic diseases. We also review the molecular mechanisms, development processes, clinical efficacies, and problems of new agents. |
format | Online Article Text |
id | pubmed-9569660 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95696602022-10-17 Therapeutic Advances in Immunotherapies for Hematological Malignancies Nogami, Ayako Sasaki, Koji Int J Mol Sci Review Following the success of immunotherapies such as chimeric antigen receptor transgenic T-cell (CAR-T) therapy, bispecific T-cell engager therapy, and immune checkpoint inhibitors in the treatment of hematologic malignancies, further studies are underway to improve the efficacy of these immunotherapies and to reduce the complications associated with their use in combination with other immune checkpoint inhibitors and conventional chemotherapy. Studies of novel therapeutic strategies such as bispecific (tandem or dual) CAR-T, bispecific killer cell engager, trispecific killer cell engager, and dual affinity retargeting therapies are also underway. Because of these studies and the discovery of novel immunotherapeutic target molecules, the use of immunotherapy for diseases initially thought to be less promising to treat with this treatment method, such as acute myeloid leukemia and T-cell hematologic tumors, has become a reality. Thus, in this coming era of new transplantation- and chemotherapy-free treatment strategies, it is imperative for both scientists and clinicians to understand the molecular immunity of hematologic malignancies. In this review, we focus on the remarkable development of immunotherapies that could change the prognosis of hematologic diseases. We also review the molecular mechanisms, development processes, clinical efficacies, and problems of new agents. MDPI 2022-09-29 /pmc/articles/PMC9569660/ /pubmed/36232824 http://dx.doi.org/10.3390/ijms231911526 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Nogami, Ayako Sasaki, Koji Therapeutic Advances in Immunotherapies for Hematological Malignancies |
title | Therapeutic Advances in Immunotherapies for Hematological Malignancies |
title_full | Therapeutic Advances in Immunotherapies for Hematological Malignancies |
title_fullStr | Therapeutic Advances in Immunotherapies for Hematological Malignancies |
title_full_unstemmed | Therapeutic Advances in Immunotherapies for Hematological Malignancies |
title_short | Therapeutic Advances in Immunotherapies for Hematological Malignancies |
title_sort | therapeutic advances in immunotherapies for hematological malignancies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569660/ https://www.ncbi.nlm.nih.gov/pubmed/36232824 http://dx.doi.org/10.3390/ijms231911526 |
work_keys_str_mv | AT nogamiayako therapeuticadvancesinimmunotherapiesforhematologicalmalignancies AT sasakikoji therapeuticadvancesinimmunotherapiesforhematologicalmalignancies |